Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cell 'Double Punch' tested against tough lymphomas

NCT ID NCT04074746

Summary

This study tested a two-part treatment for patients whose Hodgkin or Non-Hodgkin lymphoma had returned or didn't respond to other therapies. First, patients received specially prepared immune cells (NK cells) loaded with an antibody called AFM13. Then, they received the AFM13 antibody alone. The goal was to see if this combination was safe and could help the body's immune system better attack and shrink the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.